A team of investigators report on the findings from a randomized controlled trial of 3 enhanced influenza vaccines and a standard-dose vaccine in older adults.
Age and prior exposure to the H1 or B influenza virus may affect the cross-reactivity of H3-specific postvaccination responses and influence the efficacy of the seasonal influenza vaccine.
Baloxavir inhibits the endonuclease activity of the polymerase acidic protein resulting in inhibition of influenza virus replication.
Early neuraminidase inhibitor therapy may result in better outcomes in patients hospitalized with influenza B-related pneumonia.
Results of early research support further development of a synthetic universal influenza vaccine.
Despite the higher effectiveness of the quadrivalent inactivated influenza vaccine against the added B virus lineage, trivalent inactivated influenza vaccine.
Compared with patients prescribed only an antiviral, patients who are prescribed both an antiviral and antibiotic have a lower risk for 3-day respiratory hospitalization.
The FDA has approved Fluad Quadrivalent (influenza vaccine, adjuvanted; Seqirus) for active immunization in patients 65 years of age and older against influenza disease caused by influenza virus subtypes A and types B contained in the vaccine.